Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Highlighted the ~$35B addressable NASH market and described the deal as Yuhan's largest-ever out-licensing transaction, validating Korean biotech innovation in…
Characterized the agreement as part of Boehringer's broader push to build a multi-mechanism NASH portfolio, including SGLT-1/2 inhibitors and the new dual…
Reported Boehringer's decision to terminate development of BI 3006337 and return rights to Yuhan, noting Yuhan ultimately collected only ~$50M of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boehringer Ingelheim licensed Yuhan's first-in-class GLP-1/FGF21 dual agonist (a long-acting fusion protein using Genexine HyFc technology) for NASH and related liver disease. Yuhan received $40M upfront and near-term payments and is eligible for up to $830M in milestones plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / Yuhan Corporation (this deal) | 2019 | $870M | — |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
← Browse all deals · How we score deals
More: 2019 deals · Boehringer Ingelheim GmbH deals · Infectious Disease deals